Spots Global Cancer Trial Database for Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Official Title: Sun Yat-sen University Cancer Center

Study ID: NCT02362230

Conditions

Metastatic Breast Cancer

Interventions

Icotinib

Study Description

Brief Summary: Evaluating the safety and efficacy of Icotinib administered in 2-month treatments, in patients with metastatic triple-negative breast cancer that have received at least two prior treatments.

Detailed Description: This is a phase II, multi-center study. Sixty-seven patients are planned to be enrolled. All patients will receive Icotinib 125 mg BID administered for 8 weeks. Patients with a complete response, partial response or stable disease at that time may continue to be treated based on physician discretion. Follow up is then required until resolution or stabilization of any treatment-related toxicity, and patients with stable disease or objective responses must also continue evaluations until survived.